tirzepatide 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% โฌ๏ธ in combined risk ๐จ Alert: Tirzepatide No Longer
Description
The FDA has issued communications addressing risks associated with some compounded GLP-1 products, and in early 2026, FDA issued warning letters to certain telehealth companies regarding marketing claims about compounded GLP-1 products
Remaining: 20 mg
Double Dosing It can be easy to lose track of when you took your last injection, especially since tirzepatide is only administered once a week
In early phases of the GLP-1 boom, compounding was permitted under drug shortage rules
